BNP Paribas Exane analyst Navann Ty upgraded Natera (NTRA) to Neutral from Underperform with a $172 price target
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTRA:
- Natera’s Strong Position in MRD Market Bolstered by Signatera’s Impact and Potential FDA Approval
- Natera’s Oncology Advancements and Market Potential Drive Buy Rating
- Natera price target raised to $210 from $200 at BTIG
- Natera reports results from IMvigor011 clinical trial
- DE, RKLB, NTRA, QSI: Cathie Wood Loads Up on Deere and ATAI, Trims Stakes in Rocket Lab and Biotech Stocks